EMBARGOED FOR RELEASE: Sunday, Aug. 25, 2019, 5 a.m. Eastern Time
Note to journalists: Please report that this research will be presented at a meeting of the American Chemical Society.
Newswise — SAN DIEGO, Aug. 25, 2019 — For years, scientists have been trying to solve a medical mystery: Why do people with type 1 or type 2 diabetes have an increased risk of developing some forms of cancer? Today, researchers report a possible explanation for this double whammy. They found that DNA sustains more damage and gets fixed less often when blood sugar levels are high compared to when blood sugar is at a normal, healthy level, thereby increasing one’s cancer risk.
The researchers will present their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition. ACS, the world’s largest scientific society, is holding the meeting here through Thursday. It features more than 9,500 presentations on a wide range of science topics.
“It’s been known for a long time that people with diabetes have as much as a 2.5-fold increased risk for certain cancers,” says John Termini, Ph.D., who is presenting the work at the meeting. These cancers include ovarian, breast, kidney and others. “As the incidence of diabetes continues to rise, the cancer rate will likely increase, as well.”
Scientists have suspected that the elevated cancer risk for diabetics arises from hormonal dysregulation. “In people with type 2 diabetes, their insulin is not effectively carrying glucose into cells,” Termini explains. “So the pancreas makes more and more insulin, and they get what’s called hyperinsulinemia.” In addition to controlling blood glucose levels, the hormone insulin can stimulate cell growth, possibly leading to cancer. Also, most people with type 2 diabetes are overweight, and their excess fat tissue produces higher levels of adipokines than those at a healthy weight. These hormones promote chronic inflammation, which is linked to cancer. “The most common idea is that the increased cancer risk has to do with hormones,” Termini says. “That’s probably part of it, but there hasn’t been a lot of solid evidence.”
Termini, who is at City of Hope, a research and treatment center for cancer and diabetes, had a different idea. He wondered if the elevated blood glucose levels seen in diabetes could harm DNA, making the genome unstable, which could lead to cancer. So Termini and colleagues looked for a specific type of damage in the form of chemically modified DNA bases, known as adducts, in tissue culture and rodent models of diabetes. Indeed, they found a DNA adduct, called N2-(1-carboxyethyl)-2’-deoxyguanosine, or CEdG, that occurred more frequently in the diabetic models than in normal cells or mice. What’s more, high glucose levels interfered with the cells’ process for fixing it. “Exposure to high glucose levels leads to both DNA adducts and the suppression of their repair, which in combination could cause genome instability and cancer,” Termini says.
Recently, Termini and colleagues completed a clinical study that measured the levels of CEdG, as well as its counterpart in RNA (CEG), in people with type 2 diabetes. As in mice, people with diabetes had significantly higher levels of both CEdG and CEG than people without the disease.
But the team didn’t stop there. They wanted to determine the molecular reasons why the adducts weren’t being fixed properly by the cells. They identified two proteins that appear to be involved: the transcription factor HIF1α and the signaling protein mTORC1, which both show less activity in diabetes. HIF1α activates several genes involved in the repair process. “We found that if we stabilize HIF1α in a high-glucose environment, we increase DNA repair and reduce DNA damage,” Termini says. “And mTORC1 actually controls HIF1α, so if you stimulate mTORC1, you stimulate HIF1α.”
According to Termini, several drugs that stimulate HIF1α or mTORC1 already exist. The researchers plan to see if these drugs decrease cancer risk in diabetic animal models, and if so, they will test them in humans. Termini notes that metformin, a common diabetes medication that helps lower blood glucose levels, also stimulates DNA repair. “We’re looking at testing metformin in combination with drugs that specifically stabilize HIF1α or enhance mTORC1 signaling in diabetic animal models,” he says. In the meantime, a more immediate way for diabetics to reduce their cancer risk could be better control of their blood sugar. “That sounds like such an easy solution, but it’s extremely difficult for most people to maintain glycemic control,” Termini says.
A press conference on this topic will be held Monday, Aug. 26, at 3 p.m. Pacific time in the San Diego Convention Center. Reporters may check-in at the press center, Room 14B, Mezzanine Level, or watch live on Youtube http://bit.ly/acs2019sandiego. To ask questions online, sign in with a Google account.
The researchers acknowledge support and funding from the National Institutes of Health.
The American Chemical Society, the world’s largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive press releases from the American Chemical Society, contact email@example.com.
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
Hyperglycemia induced DNA damage and inhibition of DNA repair - a potential mechanistic link between diabetes and increased cancer risk
Diabetes (Type 1 and Type 2) is significantly associated with an increase in all-site cancers, yet how diabetes impacts cancer susceptibility is incompletely understood. Mechanistic hypotheses linking diabetes and cancer have invoked the mitogenic and anti-apoptotic actions of excess insulin and insulin-like growth factor 1 (IGF-1), increased adipokine secretion from fatty tissue, and steroid hormone dysregulation. However, since genomic instability plays a significant role in the initiation and promotion of cancer, we have focused on defining the mechanisms by which diabetes associated metabolic dysfunction contributes to DNA damage and reduced DNA repair. We propose that hyperglycemia-induced DNA damage and inhibition of DNA repair represent important pathological complications of diabetes which exacerbate genomic instability. We will show using tissue culture and diabetic animal models that elevated glucose significantly increases the levels of the DNA adduct N2-(1-carboxyethyl)-2’-deoxyguanosine (CEdG) and it’s RNA analog CEG, and that these adducts are significantly associated with diabetes and diabetic complications. Chronic exposure to elevated glucose also increases DNA strand breaks and inhibits nucleotide excision repair (NER), which is required for removal of CEdG from DNA. Inhibition of NER occurs at the level of gene expression due to metabolism induced destabilization of HIF1α, since many genes of the NER pathway are inducible by this transcription factor. Inhibition also occurs at the level of mTORC1 regulated translation of HIF1α, since DNA damage induces REDD1 (Regulated in Development and DNA Damage responses 1), which dephosphorylates Akt and attenuates mTOR signaling. Since pharmacological agents which stabilize HIF1α or increase translation by mTOR have been described, this raises the possibility of therapeutic intervention to enhanced DNA repair, limit genomic instability, and potentially reduce cancer risk associated with diabetes.